{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for fosdenopterin in Display Name (approximate match)
Showing 1 - 4 of 4 results
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.
Status:
US Approved Rx
(2021)
Source:
NDA214018
(2021)
Source URL:
First approved in 2021
Source:
NDA214018
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cyclic pyranopterin monophosphate is a precursor to molybdenum cofactor, which is required for the enzyme activity of sulfite oxidase, xanthine dehydrogenase/oxidase, and aldehyde oxidase. The drug is being investigated in severe molybdenum cofactor deficiency type A. In a clinical study, intravenous administration of the drug resulted in greatly improved neurodevelopmental outcome when started sufficiently early.